27 related articles for article (PubMed ID: 12674827)
1. Antibiotic Adjuvant 4-Hexylresorcinol Enhances the Efficiency of Antituberculosis Drugs.
Nikolaev YA; Mukhina TN; Potapov VD; Kuznetsov BB; El'-Registan GI; Firstova VV; Shemyakin IG; Manzenyuk OY
Bull Exp Biol Med; 2024 Feb; 176(4):466-471. PubMed ID: 38488964
[TBL] [Abstract][Full Text] [Related]
2. A biphasic nanohydroxyapatite/calcium sulphate carrier containing Rifampicin and Isoniazid for local delivery gives sustained and effective antibiotic release and prevents biofilm formation.
Qayoom I; Verma R; Murugan PA; Raina DB; Teotia AK; Matheshwaran S; Nair NN; Tägil M; Lidgren L; Kumar A
Sci Rep; 2020 Aug; 10(1):14128. PubMed ID: 32839480
[TBL] [Abstract][Full Text] [Related]
3. Hydroxylation of Antitubercular Drug Candidate, SQ109, by Mycobacterial Cytochrome P450.
Bukhdruker S; Varaksa T; Grabovec I; Marin E; Shabunya P; Kadukova M; Grudinin S; Kavaleuski A; Gusach A; Gilep A; Borshchevskiy V; Strushkevich N
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33081390
[TBL] [Abstract][Full Text] [Related]
4. Sulfamethoxazole enhances the antimycobacterial activity of rifampicin.
Macingwana L; Baker B; Ngwane AH; Harper C; Cotton MF; Hesseling A; Diacon AH; van Helden P; Wiid I
J Antimicrob Chemother; 2012 Dec; 67(12):2908-11. PubMed ID: 22875849
[TBL] [Abstract][Full Text] [Related]
5. Mutant prevention concentration of isoniazid, rifampicin and rifabutin against Mycobacterium tuberculosis.
Rodríguez JC; Cebrián L; Ruiz M; López M; Royo G
Chemotherapy; 2005 May; 51(2-3):76-9. PubMed ID: 15870500
[TBL] [Abstract][Full Text] [Related]
6. Detection of rifampicin and isoniazid resistances of Mycobacterium tuberculosis strains by particle counting immunoassay (PACIA).
Drowart A; Cambiaso CL; Huygen K; Serruys E; Portaels F; Jann E; Van Vooren JP
Int J Tuberc Lung Dis; 1997 Jun; 1(3):284-8. PubMed ID: 9432378
[TBL] [Abstract][Full Text] [Related]
7. Differential drug susceptibility of intracellular and extracellular tuberculosis, and the impact of P-glycoprotein.
Hartkoorn RC; Chandler B; Owen A; Ward SA; Bertel Squire S; Back DJ; Khoo SH
Tuberculosis (Edinb); 2007 May; 87(3):248-55. PubMed ID: 17258938
[TBL] [Abstract][Full Text] [Related]
8. [Experimental evidence for Mycobacterium tuberculosis persistence in M. tuberculosis-infected H37RV mice in the treatment with 3 first-line drugs (rifampicin, isoniazid, pyrazinamide)].
Smirnova TG; Chernousova LN; Andreevskaia SN; Nikolaeva GM
Probl Tuberk Bolezn Legk; 2004; (3):32-7. PubMed ID: 15338898
[TBL] [Abstract][Full Text] [Related]
9. Effect of rifampicin & isoniazid on cytochrome P-450 in mycobacteria.
Ramachandran G; Gurumurthy P
Indian J Med Res; 2002 Oct; 116():140-4. PubMed ID: 12674827
[TBL] [Abstract][Full Text] [Related]
10. Role of individual drugs in the chemotherapy of tuberculosis.
Mitchison DA
Int J Tuberc Lung Dis; 2000 Sep; 4(9):796-806. PubMed ID: 10985648
[TBL] [Abstract][Full Text] [Related]
11. Clinically significant drug interactions with antituberculosis agents.
Grange JM; Winstanley PA; Davies PD
Drug Saf; 1994 Oct; 11(4):242-51. PubMed ID: 7848544
[TBL] [Abstract][Full Text] [Related]
12. Potential drug targets in the Mycobacterium tuberculosis cytochrome P450 system.
Ortiz de Montellano PR
J Inorg Biochem; 2018 Mar; 180():235-245. PubMed ID: 29352597
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
